About Daniel Yadegar, M.D.:

Dr. Daniel Yadegar is a recognized leader at the intersection of healthcare, biotechnology, and life sciences. As Co-Founder and Managing Partner of Double Point Ventures, he focuses on identifying and accelerating transformative early-stage biotech companies, with a particular emphasis on life extension, regenerative medicine, cardiovascular health, and reproductive medicine.

Prior to founding Double Point Ventures, Dr. Yadegar was Co-Founder and Chief Medical Officer of Newpath Partners, a Boston-based biotech venture capital firm dedicated to supporting companies developing groundbreaking solutions in medicine, diagnostics, and therapeutics.
With a background in Internal Medicine, Cardiology, and Age Management, Dr. Yadegar brings deep clinical expertise to the biotech ecosystem. His unique blend of medical and investment experience enables him to serve as a key thought leader in life sciences, helping to translate cutting-edge scientific discoveries into impactful healthcare solutions.

Driven by a passion for scientific discovery and patient-centered innovation, Dr. Yadegar is deeply involved in clinical trials, research, and collaboration with leading scientists and entrepreneurs. “I’m a complete science geek,” he says, underscoring his commitment to staying at the forefront of biotech advancements.

His personal journey—including his experiences with fertility treatments and his family’s immigrant background—has fueled his mission to leverage technology to address global health challenges. This focus on healthspan optimization and regenerative medicine continues to shape his investment and scientific endeavors.

In addition to his leadership in biotech venture capital, Dr. Yadegar is a strong advocate for the integration of AI, machine learning, and precision medicine into clinical practice. He believes that the future of healthcare lies in harnessing emerging technologies to better understand, predict, and treat diseases—ultimately improving global quality of life.